Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Icecure Medical

Healthcare US ICCM

6.4USD
4.27(200.47%)

Last update at 2026-06-17T20:29:00Z

Day Range

3.609.54
LowHigh

52 Week Range

0.521.57
LowHigh

Fundamentals

  • Previous Close 2.13
  • Market Cap49.86M
  • Volume151545585
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-15.25300M
  • Revenue TTM3.23M
  • Revenue Per Share TTM0.07
  • Gross Profit TTM 1.45M
  • Diluted EPS TTM-0.32

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -16.97800M -9.89500M -4.69033M -4.77388M -3.53407M
Minority interest - - - - -
Net income -17.21700M -10.06600M -4.77710M -4.76031M -3.53407M
Selling general administrative 5.86M 4.12M 1.76M 1.32M 1.07M
Selling and marketing expenses 3.20M 1.92M 1.11M 1.02M 0.61M
Gross profit 1.45M 2.19M 2.66M 0.58M 0.45M
Reconciled depreciation 0.25M 0.13M 0.86M 0.54M 0.12M
Ebit -16.73900M -9.72400M -4.36162M -4.60870M -3.45282M
Ebitda -16.49100M -9.59700M -4.33736M -4.63209M -3.42202M
Depreciation and amortization 0.25M 0.13M 0.02M -0.02339M 0.03M
Non operating income net other - - - - -
Operating income -16.73900M -9.72400M -4.36162M -4.60870M -3.17030M
Other operating expenses 19.82M 13.86M 8.45M 6.27M 4.24M
Interest expense 0.24M 0.17M 0.03M 0.02M 0.06M
Tax provision - - - - -
Interest income - - 0.01M - 0.00200M
Net interest income -0.23900M -0.17100M -0.88000M -0.69800M -1.30300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.24M 0.17M 0.09M -0.01357M -1.13100M
Total revenue 3.08M 4.14M 4.08M 1.66M 1.07M
Total operating expenses 18.18M 11.92M 7.02M 5.19M 3.62M
Cost of revenue 1.64M 1.94M 1.43M 1.08M 0.62M
Total other income expense net -0.23900M -0.17100M -0.32872M -0.16518M -1.37000M
Discontinued operations - - - - -
Net income from continuing ops -16.97800M -9.89500M -15.08200M -16.53100M -13.31000M
Net income applicable to common shares -16.97800M -9.89500M -15.08200M -16.53100M -13.31000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 16.41M 30.19M 32.28M 10.34M 7.32M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.62M 1.54M 1.98M 16.19M 1.40M
Total liab 4.25M 4.77M 5.32M 5.75M 4.69M
Total stockholder equity 12.16M 25.42M 26.96M 4.58M 2.63M
Deferred long term liab - - - - -
Other current liab 2.96M 2.81M 2.03M 3.05M 3.07M
Common stock - - - 5.03M 3.47M
Capital stock 0.00000M 0.00000M 0.00000M 5.03M 3.47M
Retained earnings -90.06100M -75.40900M -58.43100M -56.96599M -48.54309M
Other liab - - 0.62M 5.65M 3.30M
Good will - - - - -
Other assets - 0.03M 0.33M 0.12M 0.14M
Cash 10.53M 23.66M 25.62M 3.50M 5.78M
Cash and equivalents - - - - -
Total current liabilities 3.87M 4.34M 4.02M 3.91M 3.63M
Current deferred revenue 0.19M 0.65M 0.88M - -
Net debt -9.93400M -23.06200M -24.71200M -3.20070M -5.53252M
Short term debt 0.22M 0.17M 0.22M 0.21M 0.13M
Short long term debt - - - - -
Short long term debt total 0.60M 0.60M 0.91M 0.30M 0.25M
Other stockholder equity 102.22M 100.83M 85.39M 56.52M 47.70M
Property plant equipment - 2.02M 1.63M 2.00M 1.31M
Total current assets 14.18M 28.13M 30.32M 9.68M 6.90M
Long term investments - - - - -
Net tangible assets - 25.42M 26.96M 14.74M 9.09M
Short term investments 0.53M - - - -
Net receivables 0.23M 1.32M 0.77M 0.88M 0.36M
Long term debt - - - - -
Inventory 2.27M 2.86M 1.96M 1.14M 0.72M
Accounts payable 0.50M 0.71M 0.88M 0.64M 0.43M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.03M 0.33M 0.04M 0.04M
Deferred long term asset charges - - - - -
Non current assets total 2.23M 2.06M 1.96M 0.66M 0.42M
Capital lease obligations 0.60M 0.60M 0.91M 0.97M 0.85M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.89100M 4.62M -15.00000M -15.00000M -15.00000M
Change to liabilities -0.16700M 0.24M 0.34M 7.90M 1.70M
Total cashflows from investing activities -0.89100M 3.79M -15.81300M -0.35400M -0.24200M
Net borrowings - - -0.55300M -0.36400M -3.48600M
Total cash from financing activities 13.58M 30.89M 5.95M 3.06M 5.98M
Change to operating activities 0.91M -2.14100M 1.52M 0.41M 0.35M
Net income -16.97800M -9.89500M -4.69033M -4.77388M -3.53407M
Change in cash -1.96200M 22.12M -2.72022M 1.22M 2.85M
Begin period cash flow 25.62M 3.50M 6.22M 4.56M 1.34M
End period cash flow 23.66M 25.62M 3.50M 5.78M 4.19M
Total cash from operating activities -14.29200M -12.60500M -3.71787M -1.74194M -3.06383M
Issuance of capital stock 13.57M 30.55M 6.20M 3.37M 6.91M
Depreciation 0.25M 0.13M 0.27M 0.16M 0.03M
Other cashflows from investing activities - -0.29600M -0.04800M -0.04800M -0.04800M
Dividends paid - - - - -
Change to inventory -0.90200M -0.89100M -0.36977M -0.00693M -0.37598M
Change to account receivables 0.38M -0.36200M -0.24500M 0.62M -0.59800M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.00200M 0.34M -0.08117M -0.31102M -0.92826M
Change to netincome - 0.32M 1.85M 1.06M 1.39M
Capital expenditures 0.89M 0.53M 0.24M 0.10M 0.06M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.21M -3.15800M 0.13M 2.57M 0.00956M
Stock based compensation 1.86M 0.32M 0.23M 0.36M 0.21M
Other non cash items 0.36M 0.00500M 0.31M -0.05949M 0.21M
Free cash flow -15.18300M -13.13800M -3.95578M -1.84417M -3.12809M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ICCM
Icecure Medical		 4.27 200.47% 6.40 - - 17.70 4.70 14.46 -3.0616
ABT
Abbott Laboratories		 -2.12 2.34% 88.50 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -9.44 3.04% 301.14 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -3.18 3.91% 78.14 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.97 4.20% 44.95 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Icecure Medical

7 Ha?Eshel Street, Caesarea, Israel, 3079504

Key Executives

Name Title Year Born
Mr. Eyal Shamir CEO & Director 1961
Mr. Ronen Tsimerman CPA CFO & COO 1969
Ms. Tlalit Bussi Tel-Tzure VP of Bus. Devel. & Global Marketing 1971
Ms. Merav Nir Dotan VP of HR 1969
Mr. Naum Muchnik VP of Research, Devel. & Engineering 1976
Mr. Shay Levav VP of Regulatory and Quality Assurance & Clinical Applications 1977
Ms. Tlalit Bussi Tel-Tzure Vice President of Business Development & Global Marketing 1971
Ms. Merav Nir Dotan Vice President of Human Resources 1969
Ms. Galit Malik Vice President of Operations & Service 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.